Abbott (NYSE: ABT), a global healthcare company, announced on Monday that it has received approval from the United States Food and Drug Administration (FDA) for its Portico with FlexNav transcatheter aortic valve replacement system for the treatment of people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.
The company continues to provide range of structural heart solutions that include innovative, minimally invasive therapies to repair or replace diseased or damaged heart valves or close openings in the heart with the new TAVR (also referred to as TAVI, or transcatheter aortic valve implantation) advancement.
Raj Makkar, MD, associate director of Interventional Technologies at Cedars-Sinai's Smidt Heart Institute, said, 'For people in the US suffering from aortic stenosis and unable to have surgery, the Portico with FlexNav system offers a safe and effective treatment option.'
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT